In metastatic NSCLC patients receiving anti-PD-1 treatment, the response rate was only 16.7% when the number of CD8+ TILs was < 886/mm2; the response rate increased to 60% when the number of CD8+ TILs ranged from 886–1899/mm2 (23). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.